Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Node Negative Breast Cancer”

2,722 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 2,722 results

Testing effectiveness (Phase 2)WithdrawnNCT03872505
What this trial is testing

Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Cedars-Sinai Medical Center
Large-scale testing (Phase 3)Study completedNCT01317108
What this trial is testing

Prognostic and Predictive Impact of uPA/PAI-1

Who this might be right for
Breast Cancer
Universitätsklinikum Hamburg-Eppendorf 689
Early research (Phase 1)Study completedNCT02719691
What this trial is testing

Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer

Who this might be right for
Metastatic Breast CancerSolid Tumors
University of Colorado, Denver 47
Early research (Phase 1)Study completedNCT04105582
What this trial is testing

Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Universidad Nacional de Colombia 5
Early research (Phase 1)Ended earlyNCT01238133
What this trial is testing

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+6 more
National Cancer Institute (NCI) 14
Testing effectiveness (Phase 2)Ended earlyNCT00597597
What this trial is testing

Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Rush University Medical Center 11
Testing effectiveness (Phase 2)Looking for participantsNCT06361940
What this trial is testing

Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer

Who this might be right for
Breast Cancer
Medical College of Wisconsin 100
Not applicableActive Not RecruitingNCT04993625
What this trial is testing

Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm (ASLAN) Study

Who this might be right for
Breast Cancer
Jeong Eon Lee 178
Testing effectiveness (Phase 2)Study completedNCT03822468
What this trial is testing

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 376
Testing effectiveness (Phase 2)UnknownNCT05340413
What this trial is testing

Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.

Who this might be right for
HER2-negative Breast CancerMetastatic Breast CancerTriple Negative Breast Cancer
SOLTI Breast Cancer Research Group 63
Large-scale testing (Phase 3)Study completedNCT01150513
What this trial is testing

Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer

Who this might be right for
Breast Cancer
Chinese Academy of Medical Sciences 320
Very early researchStudy completedNCT01467310
What this trial is testing

Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212

Who this might be right for
Breast Cancer
UNC Lineberger Comprehensive Cancer Center 15
Testing effectiveness (Phase 2)WithdrawnNCT05234606
What this trial is testing

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

Who this might be right for
Urothelial CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer+2 more
Silverback Therapeutics
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06750848
What this trial is testing

Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer

Who this might be right for
Advanced Breast Cancer
Jundong Wu 48
Not applicableStudy completedNCT03852953
What this trial is testing

Under- and Overdiagnosis in BreastScreen Norway

Who this might be right for
Breast Cancer
Norwegian Institute of Public Health 3,915
Not applicableNot Yet RecruitingNCT06418139
What this trial is testing

Association of Pembrolizumab Infusion Time and Efficacy in Patients With Non-metastatic Triple-negative Breast Cancer (TNBC) Treated With Neoadjuvant Chemotherapy and Immunotherapy

Who this might be right for
Non-Metastatic Breast Carcinoma
Assistance Publique - Hôpitaux de Paris 450
Not applicableUnknownNCT04683757
What this trial is testing

The Establishment of a Survival Prediction Model for ER Positive / HER-2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
Ying Wang 288
Testing effectiveness (Phase 2)Looking for participantsNCT04954599
What this trial is testing

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
Maastricht University Medical Center 126
Large-scale testing (Phase 3)Active Not RecruitingNCT04191499
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 325
Testing effectiveness (Phase 2)Looking for participantsNCT04569747
What this trial is testing

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerInvasive Carcinoma of the BreastBreast Cancer+3 more
Dana-Farber Cancer Institute 375
Load More Results